Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Seizures: Classification

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Observation of the Structure and Dynamics of Water in Aqueous Alkaline Chloride Solutions under Gigapascal Pressure by Neutron Scattering.

The journal of physical chemistry letters·2026

Same author

Association between voltage-gated sodium channel gene polymorphisms and chronic oxaliplatin-induced peripheral neuropathy in Japanese patients with colorectal cancer.

Journal of pharmaceutical health care and sciences·2026

Same author

Singular Continuous and Nonreciprocal Phonons in Quasicrystal AlPdMn.

Physical review letters·2024

Same author

Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.

Annals of palliative medicine·2023

Same author

A Joint Multitask Learning Model for Cross-sectional and Longitudinal Predictions of Visual Field Using OCT.

Ophthalmology science·2022

Same author

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study.

Journal of clinical medicine·2022

Search research articles

Related Experiment Videos

[Epilepsy and driving].

Masato Matsuura

Nihon Rinsho. Japanese Journal of Clinical Medicine

|June 11, 2014

Summary

This summary is machine-generated.

Japan amended its Road Traffic Act and introduced a new Criminal Law Act in 2013 to enhance road safety. These laws impose penalties for false disease declarations and severe consequences for drug- or disease-impaired driving.

Related Experiment Videos

Area of Science:

Legal and Criminological Studies
Public Health Policy
Transportation Safety

Context:

Recent amendments to Japanese traffic laws in 2013 address critical safety concerns.
Legislation targets individuals with specific diseases or under the influence of drugs, posing risks on the road.

Purpose:

To outline the key provisions of Japan's revised Road Traffic Act and new Criminal Law Act.
To detail the penalties for non-compliance and the scope of the new regulations.

Summary:

The Road Traffic Act now penalizes false statements on disease declaration forms and introduces a doctor's voluntary notification system for high-risk drivers.
The New Criminal Law Act establishes severe penalties, including up to 15 years imprisonment, for causing death or injury while driving under the influence of drugs or specific diseases.

Impact:

These legislative changes aim to reduce traffic accidents caused by impaired or medically unfit drivers.
The laws are set for enforcement in 2014, with provisions for future reviews and considerations to prevent discrimination.